Adjustment of @entity2399 infusion rate in @entity1 with XXXX .

@entity1 @entity3152 @entity2399 @entity460 @entity1011 @entity1760
OBJECTIVE: Our purpose was to investigate factors that might influence serum @entity1760 levels during intravenous @entity2399 tocolytic therapy. STUDY DESIGN: Thirty-three @entity1 receiving @entity2399 for @entity3152 participated in this prospective, observational study. Gestational ages were 24 to 34 weeks. Four groups of @entity1 were identified according to the maintenance @entity1760 infusion rate required for arresting @entity3152 after 5 g of therapy induction: 1.5, 2, 2.5, and 3 g/h. Serum @entity1760 samples were drawn after a predefined period of at least 18 hours of arrested @entity3152 , at a minimum of every 6 hours. Variables examined included serum albumin; serum protein; serum ionized @entity460 ; serum @entity1011 ; @entity1011 clearance; 24-hour urine output; maternal height, weight, body surface area; and body mass index. RESULTS: By use of a multivariate stepwise regression model we identified four variables that independently and significantly contributed to the model: @entity1760 infusion rate (P < .001); total serum protein level (P < .001); serum @entity1011 level (P = .009); and maternal weight squared (P = .026). Seventy-two percent of the variance was accounted for by use of these parameters. A predictive linear model, developed to relate these factors, produced the following formula: Suggested @entity1760 infusion rate = 0.89 x Serum @entity1760 concentration (mg/dL) - 3.16 x Serum @entity1011 (mg/dL) - 0.66 x Serum total proteins (g/dL) + 0.0001 x (maternal weight)2 (kg) + 2.30. CONCLUSIONS: Serum @entity1011 , serum protein, and maternal weight can be used to adjust the dose of @entity2399 in @entity1 with @entity3152 to achieve therapeutic serum levels of @entity1760 more rapidly and safely.
